SCHEMBL10101738

SCHEMBL10101738

C/C(=N\OCc1ccc(C)cc1)c1cccc(O)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PPARG P37231 12/20 0.50
PPARA Q07869 11/20 0.50
S1PR1 P21453 1/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
MAOB P27338 1/20 0.46
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10106876 0.85 PPARG (0.50) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101731 0.84 L3MBTL1 (0.68) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101733 0.82 S1PR1 (0.60) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10102004 0.81 MAOB (0.53) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101726 0.81 S1PR1 (0.48) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101741 0.81 S1PR1 (0.48) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101735 0.81 S1PR1 (0.50) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL9449576 0.80 KDM4E (0.53) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL9449579 0.80 KDM4E (0.53) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG
SCHEMBL10101811 0.79 S1PR1 (0.46) L3MBTL1RAB9ANPC1SMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046255-A1 NON-STEROIDAL COMPOUNDS PTGES2, PTGES, PTGES3 L3MBTL1 4843/4885RAB9A 3908/4885NPC1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.